CD
LCTX icon

Carl Domino’s Lineage Cell Therapeutics LCTX Stock Holding History

Carl Domino’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$105K Buy
42,291
+4,572
+12% +$11.3K 0.13% 108
2017
Q2 		$104K Hold
37,719
– – 0.12% 117
2017
Q1 		$114K Hold
37,719
– – 0.12% 114
2016
Q4 		$119K Buy
37,719
+20,574
+120% +$63.2K 0.13% 108
2016
Q3 		$55K Buy
+17,145
New +$47.4K 0.05% 127

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Carl Domino's LCTX Position: Q3 2017 in Review

Carl Domino increased its Lineage Cell Therapeutics (LCTX) stake by 12% in Q3 2017, buying an estimated $11.3K and bringing the position to 42,291 shares worth $105K. The position accounts for 0.13% of the portfolio, ranked #108.

Carl Domino first reported a position in LCTX in Q3 2016 and has held it in 5 quarters since. The position peaked at $119K in Q4 2016. 102 funds tracked by Wall St. Rank hold LCTX as of Q3 2017.

  • Carl Domino held 42,291 shares of Lineage Cell Therapeutics worth $105K as of Q3 2017.
  • Carl Domino bought 4,572 Lineage Cell Therapeutics shares in Q3 2017, an estimated $11.3K.
  • Lineage Cell Therapeutics made up 0.13% of Carl Domino's portfolio in Q3 2017, its #108 holding.
  • Carl Domino first reported a position in Lineage Cell Therapeutics in Q3 2016 and has held it in 5 quarters since.
  • Carl Domino's Lineage Cell Therapeutics position peaked at $119K in Q4 2016.
  • 102 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2017.

Based on Carl Domino's 13F filing for Q3 2017, filed 7 Nov 2017.